Market closed
Merck KGaA/€MRK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
€MRK
Sector
Trading on
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
59,020
Website
Merck KGaA Metrics
BasicAdvanced
€51B
18.25
€6.39
0.74
€2.20
1.89%
Price and volume
Market cap
€51B
Beta
0.74
52-week high
€176.25
52-week low
€110.45
Average daily volume
406K
Dividend rate
€2.20
Financial strength
Current ratio
1.191
Quick ratio
0.686
Long term debt to equity
23.333
Total debt to equity
34.351
Dividend payout ratio (TTM)
37.13%
Interest coverage (TTM)
17.13%
Management effectiveness
Return on assets (TTM)
4.80%
Return on equity (TTM)
9.82%
Valuation
Price to earnings (TTM)
18.248
Price to revenue (TTM)
2.395
Price to book
1.7
Price to tangible book (TTM)
11.32
Price to free cash flow (TTM)
20.939
Dividend yield (TTM)
1.89%
Forward dividend yield
1.89%
Growth
Revenue change (TTM)
0.78%
Earnings per share change (TTM)
-1.60%
3-year revenue growth (CAGR)
2.43%
3-year earnings per share growth (CAGR)
-3.14%
3-year dividend per share growth (CAGR)
5.95%
What the Analysts think about Merck KGaA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Merck KGaA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merck KGaA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merck KGaA News
AllArticlesVideos
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
24/7 Wall Street·20 hours ago
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 day ago
Microfiltration Membranes Market Research - Global Forecast to 2029 with Merck, Sartorius, and Pall Leading
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Market closed
Upcoming events
Apr28
Merck KGaA
Dividend·Ex-dividend
Apr30
Merck KGaA
Dividend·Payment
€2.20
Per share
FAQs
What’s the current market cap for Merck KGaA stock?
Merck KGaA (MRK) has a market cap of €51B as of April 19, 2025.
What is the P/E ratio for Merck KGaA stock?
The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 18.25 as of April 19, 2025.
Does Merck KGaA stock pay dividends?
Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of April 19, 2025, the dividend rate is €2.2 and the yield is 1.89%. Merck KGaA has a payout ratio of 37.13% on a trailing twelve-month basis.
When is the next Merck KGaA dividend payment date?
The next Merck KGaA (MRK) dividend payment is scheduled for April 30, 2025.
What is the beta indicator for Merck KGaA?
Merck KGaA (MRK) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.